Background: Bacterial meningitis is a serious medical disorder that should be treated as
soon as possible. Aim: The effect of ansamycin as a nanoformulation on
Escherichia coli-
induced meningitis was investigated. Materials and Methods: By injecting
Escherichia
coli directly into the brains of Swiss Albino mice, an experimental meningitis model was
established. Results: As expected, TNF-α, IL-6, and IL-10 secretion was stimulated,
following neutrophil infiltration. Additionally, the BBB’s vasopermeability was raised.
Ansamcyin nanoparticles were delivered to assess their therapeutic potential in preventing
bacterial meningitis caused by
Escherichia coli. Ansamycin nanoparticle-treated mice
produced less tumour necrosis factor alpha and interleukins when brain tissue was
stained, compared to nontreated mice.
E. coli-induced increases in the permeability of
the blood-brain barrier and infiltration of inflammatory neutrophils were also prevented.
Conclusion: These findings suggest that ansamycin nanoparticles could be used to treat
bacterial meningitis. It has been shown that ansamycin nanoparaticles can prevent
the mice from
E. coli-induced mortality, therefore enhancing their outcome.